TYVASO DPI IS NOW APPROVED

Learn more
Skip to main content

FOR US HEALTHCARE PROFESSIONALS ONLY

For the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

SELECT INDICATION
Search Button
Skip to main content
FOR US HEALTHCARE PROFESSIONALS ONLY
logo
logo
SELECT INDICATION

ABOUT PH-ILD

WHAT IS TYVASO?

CLINICAL STUDIES

STARTING TYVASO

RESOURCES & SUPPORT

IMPACT

PH significantly impacts patients with ILD1,2

PH in patients with ILD is associated with:

Increased need for supplemental oxygen2-4

Increased risk for acute exacerbations5

Decreased exercise capacity based on 6MWT and CPET3,6

Worsened prognosis1-4,7-9

PH is an increase in mean pulmonary arterial pressure (mPAP)2

Even mild increases in mPAP can impact patients with ILD (eg, IPF)3

About half of patients with both IPF and PH have slightly elevated mPAP of 25-30 mm Hg2

Limiting screening to severe PH may miss many patients with mild PH who have a worsened prognosis.

6MWT=6-minute walk test; CPET=cardiopulmonary exercise testing; ILD=interstitial lung disease; IPF=idiopathic pulmonary fibrosis; PH=pulmonary hypertension.

LEARN MORE ABOUT THE PREVALENCE OF PH-ILD

The information contained in this section of the site is clinical in nature and specifically created for healthcare professionals. If you are not a US healthcare professional, please click CLOSE to return to the consumer section of the site.

CLOSE

Yes, I am a US healthcare professional and would like to continue.